JP2021504326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504326A5 JP2021504326A5 JP2020528027A JP2020528027A JP2021504326A5 JP 2021504326 A5 JP2021504326 A5 JP 2021504326A5 JP 2020528027 A JP2020528027 A JP 2020528027A JP 2020528027 A JP2020528027 A JP 2020528027A JP 2021504326 A5 JP2021504326 A5 JP 2021504326A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- compound
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 21
- 229910052805 deuterium Inorganic materials 0.000 claims description 18
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 14
- 208000020925 Bipolar disease Diseases 0.000 claims description 12
- 230000001149 cognitive effect Effects 0.000 claims description 11
- 230000007812 deficiency Effects 0.000 claims description 11
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 10
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 10
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 208000024714 major depressive disease Diseases 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 206010014599 encephalitis Diseases 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000000561 anti-psychotic effect Effects 0.000 claims description 4
- 208000028683 bipolar I disease Diseases 0.000 claims description 4
- 208000025307 bipolar depression Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 201000010901 lateral sclerosis Diseases 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 6
- 208000027060 subjective cognitive decline Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023091296A JP7733058B2 (ja) | 2017-11-22 | 2023-06-02 | Ｄ－セリンの重水素化類似体およびその使用 |
| JP2025106389A JP2025138735A (ja) | 2017-11-22 | 2025-06-24 | Ｄ－セリンの重水素化類似体およびその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590109P | 2017-11-22 | 2017-11-22 | |
| US62/590,109 | 2017-11-22 | ||
| US201862636081P | 2018-02-27 | 2018-02-27 | |
| US62/636,081 | 2018-02-27 | ||
| US201862636427P | 2018-02-28 | 2018-02-28 | |
| US62/636,427 | 2018-02-28 | ||
| US201862755157P | 2018-11-02 | 2018-11-02 | |
| US62/755,157 | 2018-11-02 | ||
| PCT/US2018/062263 WO2019104179A1 (en) | 2017-11-22 | 2018-11-21 | Deuterated analogs of d-serine and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023091296A Division JP7733058B2 (ja) | 2017-11-22 | 2023-06-02 | Ｄ－セリンの重水素化類似体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504326A JP2021504326A (ja) | 2021-02-15 |
| JP2021504326A5 true JP2021504326A5 (https=) | 2021-12-23 |
| JP7518765B2 JP7518765B2 (ja) | 2024-07-18 |
Family
ID=64755715
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528027A Active JP7518765B2 (ja) | 2017-11-22 | 2018-11-21 | Ｄ－セリンの重水素化類似体およびその使用 |
| JP2023091296A Active JP7733058B2 (ja) | 2017-11-22 | 2023-06-02 | Ｄ－セリンの重水素化類似体およびその使用 |
| JP2025106389A Pending JP2025138735A (ja) | 2017-11-22 | 2025-06-24 | Ｄ－セリンの重水素化類似体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023091296A Active JP7733058B2 (ja) | 2017-11-22 | 2023-06-02 | Ｄ－セリンの重水素化類似体およびその使用 |
| JP2025106389A Pending JP2025138735A (ja) | 2017-11-22 | 2025-06-24 | Ｄ－セリンの重水素化類似体およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20200368193A1 (https=) |
| EP (2) | EP4560024A3 (https=) |
| JP (3) | JP7518765B2 (https=) |
| KR (1) | KR102916897B1 (https=) |
| CN (1) | CN111491629A (https=) |
| AU (2) | AU2018371784B2 (https=) |
| BR (1) | BR112020010156A2 (https=) |
| CA (1) | CA3082834A1 (https=) |
| IL (2) | IL274585B2 (https=) |
| MX (1) | MX2020005336A (https=) |
| PL (1) | PL3713557T3 (https=) |
| TW (1) | TWI886093B (https=) |
| WO (1) | WO2019104179A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7518765B2 (ja) | 2017-11-22 | 2024-07-18 | コンサート ファーマシューティカルズ インコーポレイテッド | Ｄ－セリンの重水素化類似体およびその使用 |
| RU2738873C2 (ru) * | 2018-12-29 | 2020-12-17 | Общество С Ограниченной Ответственностью "Сольвекс" (Ооо "Сольвекс") | Препарат для магнитно-резонансной томографии, содержащий дейтерированный саркозин, и способ диагностики с использованием этого препарата |
| WO2020206367A1 (en) * | 2019-04-03 | 2020-10-08 | Concert Pharmaceuticals, Inc. | Processes for the preparation of deuterated d-serine |
| WO2020243638A1 (en) * | 2019-05-30 | 2020-12-03 | Concert Pharmaceuticals, Inc. | Methods of treatment with deuterated analogs of d-serine |
| WO2021127572A1 (en) * | 2019-12-19 | 2021-06-24 | Intra-Cellular Therapies, Inc. | Methods of schizophrenia treatment |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582931A (en) | 1984-12-24 | 1986-04-15 | Merck & Co., Inc. | Preparation of 2-Deutero-D-serine |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| PT871440E (pt) | 1995-12-07 | 2006-07-31 | Daniel C Javitt | Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina |
| US6361957B1 (en) | 1999-08-03 | 2002-03-26 | Glytech, Inc. | Assay for D-serine transport antagonist and use for treating psychosis |
| US5845286A (en) | 1996-12-24 | 1998-12-01 | Colizza; Vincent | Date value reduction system |
| EP1073432B1 (en) * | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| US6258605B1 (en) | 1999-03-26 | 2001-07-10 | Neo Gen Screening, Inc. | Clinical method for the genetic screening of newborns using tandem mass spectrometry |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| PT1104760E (pt) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| CN1255185C (zh) | 2001-05-03 | 2006-05-10 | 弗·哈夫曼-拉罗切有限公司 | 无定形甲磺酸奈非那韦的药物剂型 |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| IL154318A (en) * | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
| MX2007003731A (es) | 2004-09-29 | 2007-08-14 | Johnson & Johnson | Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables. |
| JP5266042B2 (ja) | 2005-04-11 | 2013-08-21 | エール ユニヴァーシティ | 統合失調症前駆症の治療方法 |
| EP1934201A1 (en) | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US20080103122A1 (en) | 2006-09-05 | 2008-05-01 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| IL188681A0 (en) | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
| WO2012019106A2 (en) | 2010-08-06 | 2012-02-09 | Board Of Regents Of The University Of Nebraska | Positive and negative modulators of nmda receptors |
| US9040581B1 (en) | 2013-02-21 | 2015-05-26 | The Florida State University Research Foundation, Inc. | Methods of treatment using D-serine |
| EP3003378B1 (en) * | 2013-05-28 | 2019-10-02 | Sarah Herzog Memorial Hospital, Ezrat Nashim Association | Use of nmdar agonists for the treatment of autoimmune-induced glutamatergic receptor dysfunction |
| WO2014205074A2 (en) | 2013-06-18 | 2014-12-24 | The Trustees Of Columbia University In The City Of New York | Devices, compositions and methods for imaging with raman scattering |
| WO2015160470A2 (en) * | 2014-03-20 | 2015-10-22 | The Trustees Of Princeton University | Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease |
| GB201521903D0 (en) | 2015-12-11 | 2016-01-27 | Electrophoretics Ltd | Isorbaric mass labels |
| WO2017210097A1 (en) | 2016-06-02 | 2017-12-07 | Metabolon, Inc. | Mass spectrometry method for detection and quantitation of metabolites |
| JP7518765B2 (ja) * | 2017-11-22 | 2024-07-18 | コンサート ファーマシューティカルズ インコーポレイテッド | Ｄ－セリンの重水素化類似体およびその使用 |
| WO2020243650A1 (en) | 2019-05-29 | 2020-12-03 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
-
2018
- 2018-11-21 JP JP2020528027A patent/JP7518765B2/ja active Active
- 2018-11-21 PL PL18825828.9T patent/PL3713557T3/pl unknown
- 2018-11-21 MX MX2020005336A patent/MX2020005336A/es unknown
- 2018-11-21 IL IL274585A patent/IL274585B2/en unknown
- 2018-11-21 CN CN201880081985.1A patent/CN111491629A/zh active Pending
- 2018-11-21 KR KR1020207017407A patent/KR102916897B1/ko active Active
- 2018-11-21 EP EP25156008.2A patent/EP4560024A3/en active Pending
- 2018-11-21 US US16/766,194 patent/US20200368193A1/en not_active Abandoned
- 2018-11-21 EP EP18825828.9A patent/EP3713557B1/en active Active
- 2018-11-21 CA CA3082834A patent/CA3082834A1/en active Pending
- 2018-11-21 IL IL322463A patent/IL322463A/en unknown
- 2018-11-21 BR BR112020010156-7A patent/BR112020010156A2/pt unknown
- 2018-11-21 WO PCT/US2018/062263 patent/WO2019104179A1/en not_active Ceased
- 2018-11-21 AU AU2018371784A patent/AU2018371784B2/en active Active
- 2018-11-22 TW TW107141705A patent/TWI886093B/zh active
-
2019
- 2019-07-02 US US16/459,916 patent/US10668036B2/en active Active
-
2020
- 2020-05-27 US US16/884,652 patent/US12029712B2/en active Active
-
2023
- 2023-06-02 JP JP2023091296A patent/JP7733058B2/ja active Active
-
2024
- 2024-06-03 US US18/731,580 patent/US20250000830A1/en active Pending
-
2025
- 2025-01-17 AU AU2025200345A patent/AU2025200345A1/en active Pending
- 2025-06-24 JP JP2025106389A patent/JP2025138735A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504326A5 (https=) | ||
| JP2023527575A5 (https=) | ||
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| WO2019104179A4 (en) | Deuterated analogs of d-serine and uses thereof | |
| JP2020514318A5 (https=) | ||
| JP2020505408A5 (https=) | ||
| EP4275753A3 (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| ES2971230T3 (es) | Compuestos inhibidores de VMAT2 y composiciones de los mismos | |
| ES2732442T3 (es) | Compuestos orgánicos | |
| JP2020526534A5 (https=) | ||
| JP2022524974A5 (https=) | ||
| RU2010129929A (ru) | Производные 5-оксо-3-пирролидинкарбоксамида в качестве модуляторов р2х7 | |
| JP2020507602A5 (https=) | ||
| JP2018537535A5 (https=) | ||
| JP2020023496A6 (ja) | 有機化合物 | |
| AP2002002465A0 (en) | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or Vitamin E for the treatment of cognitive disorders. | |
| JP2015531764A5 (https=) | ||
| JP2017511377A5 (https=) | ||
| JP2019529460A5 (https=) | ||
| JP2022539152A5 (https=) | ||
| JP2023509944A5 (https=) | ||
| JP2014520140A5 (https=) | ||
| JP2016537432A5 (https=) | ||
| JP2022510587A5 (https=) | ||
| JP2006516643A5 (https=) |